Objective To investigate the clinical efficacy of imatinib mesylate combined with vindesine+dexametha-sone+peraspartase+demethoxydaunorubicin(VDLD)regimen in the induction treatment of acute lymphoblastic leuke-mia in children.Method A total of 104 children with acute lymphoblastic leukemia were divided into control group(n=52)and observation group(n=52)according to different chemotherapy regimens.The control group was treated with VDLD regimen,and the observation group was treated with imatinib mesylate combined with VDLD regimen.The clini-cal efficacy,tumor markers[vascular endothelial growth factor(VEGF),vascular endothelial growth factor receptor(VEGFR),basic fibroblast growth factor(bFGF)]levels,incidence of adverse reactions and prognosis of the two groups were compared.Result The total effective rate and 5-year survival rate in observation group were higher than those in control group,and 5-year recurrence rate was lower than that in control group,and the differences were statistically signif-icant(P<0.05).After treatment,the levels of VEGF,VEFGR and bFGF in two groups were lower than those before treat-ment,and the levels of VEGF,VEFGR and bFGF in observation group were lower than those in control group,and the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse re-actions between the two groups(P>0.05).Conclusion The combination of imatinib mesylate and VDLD regimen in the induction treatment of acute lymphoblastic leukemia in children can improve the clinical efficacy,reduce the recurrence rate,and without increasing adverse reactions,with high safety.
NETL
NSTL
万方数据
